N-Zyme Biomedical Secures $4.6 Million Series A Financing to Advance Phase 2 Clinical Programs for Novel Reflux Disease Therapy
N-Zyme Biomedical has successfully completed its Series A financing round, raising approximately US$4.6 million to support the continued clinical development of its innovative therapeutic platform for reflux disease. The funding marks a major milestone for the biotechnology company as it accelerates the advancement of its lead drug candidate through Phase 2 clinical studies and expands development of its proprietary pepsin inhibitor technology.
The new capital will primarily be used to advance the company’s ongoing and planned Phase 2 clinical programs targeting laryngopharyngeal reflux (LPR) and proton pump inhibitor (PPI)-refractory gastroesophageal reflux disease (GERD). Beyond these immediate clinical objectives, the financing also positions N-Zyme to further explore the broader potential of its novel therapeutic platform across multiple reflux-related disorders where significant unmet medical needs remain.
Strengthening the Company’s Clinical Development Strategy
The successful financing provides N-Zyme with the financial resources necessary to continue executing its development strategy at a critical stage in the company’s growth. By supporting multiple clinical programs simultaneously, the investment enables the company to generate additional clinical evidence for its lead investigational therapy while strengthening its long-term product pipeline.
Unlike many early-stage biotechnology companies that focus on a single indication, N-Zyme is developing a platform technology with the potential to address several forms of reflux disease. The company’s scientific approach centers on targeting pepsin, an enzyme increasingly recognized as an important contributor to tissue damage and persistent symptoms in patients with reflux disorders.
With additional funding now secured, the company intends to accelerate patient enrollment, clinical operations, regulatory activities, manufacturing preparations, and broader scientific initiatives that will support future development.
Broad Support from Investors
The Series A financing attracted participation from a diverse group of investors who share confidence in both the company’s scientific approach and its commercial potential.
The investor syndicate included healthcare professionals, experienced entrepreneurs, venture capital firms, and strategic investors with an interest in advancing innovative therapies for gastrointestinal diseases. Their participation reflects growing recognition of the unmet medical need in reflux disease as well as confidence in N-Zyme’s differentiated treatment strategy.
The financing also represents external validation of the company’s progress to date, including its advancement into Phase 2 clinical development and the growing body of scientific evidence supporting pepsin inhibition as a therapeutic target.
Leadership Highlights an Important Milestone
Franco Vigile, Co-Founder and Chief Executive Officer of N-Zyme Biomedical, described the financing as a defining moment in the company’s evolution.
He emphasized that the successful completion of the Series A round represents more than simply securing additional capital. According to Vigile, it validates the company’s scientific foundation, strategic vision, and the dedication of its research and development team.
He expressed appreciation to investors for their confidence in the company’s mission to transform the treatment landscape for reflux disease, noting that their support will allow N-Zyme to accelerate development efforts aimed at delivering a first-in-class therapy for millions of patients worldwide.
Vigile added that the financing marks the beginning of a new stage of growth, positioning N-Zyme to continue expanding its clinical programs while building a biotechnology company focused on addressing longstanding unmet needs in gastrointestinal medicine.
Supporting Rigorous Clinical Research
Dr. Nikki Johnston, Co-Founder and Chief Scientific Officer of N-Zyme Biomedical, highlighted the scientific significance of the financing.
She explained that the new funding provides the resources needed to continue evaluating the company’s investigational therapy through carefully designed clinical studies intended to generate robust evidence regarding safety and efficacy.
According to Johnston, N-Zyme remains committed to advancing high-quality clinical research while building scientific understanding of pepsin’s role in reflux disease.
She noted that continued investment in clinical development will help determine the full therapeutic potential of the company’s platform while supporting future regulatory interactions and product development.
Dr. Johnston also emphasized that the company’s long-term goal is to redefine how reflux disease is treated by addressing biological mechanisms that are not adequately targeted by current therapies.
A Different Approach to Treating Reflux Disease
Current treatment options for reflux disease primarily focus on reducing stomach acid production.
Proton pump inhibitors remain the standard of care for many patients with GERD; however, a substantial number of individuals continue to experience persistent symptoms despite acid suppression therapy. This is particularly true for patients with laryngopharyngeal reflux and those classified as PPI-refractory.
N-Zyme’s investigational therapy takes a fundamentally different approach.
Rather than targeting gastric acid, the therapy is designed to inhibit pepsin, a digestive enzyme that has emerged as an important contributor to tissue injury in reflux disease.
Research suggests that pepsin may remain active even when gastric acid levels are reduced and can continue damaging sensitive tissues in the throat, esophagus, and upper airway. This mechanism may help explain why many patients continue experiencing symptoms despite long-term use of acid-suppressing medications.
By directly targeting pepsin, N-Zyme aims to address an underlying driver of disease rather than simply reducing acid exposure.
If successful, this approach could represent an important advancement in the management of reflux disorders, particularly for patients who do not achieve adequate symptom control with existing therapies.
Advancing Phase 2 Clinical Programs
The proceeds from the Series A financing will support several important development initiatives.
A primary focus will be the continued advancement of the company’s ongoing Phase 2 clinical study evaluating its lead therapeutic candidate in patients with laryngopharyngeal reflux.
In parallel, N-Zyme plans to initiate additional Phase 2 development in patients with proton pump inhibitor-refractory gastroesophageal reflux disease, an area where treatment options remain limited.
The financing will also support:
- Continued regulatory interactions with health authorities.
- Manufacturing activities required for ongoing and future clinical studies.
- Expansion of scientific research programs.
- Business development initiatives.
- General corporate operations supporting long-term growth.
These investments are intended to strengthen both the company’s current clinical portfolio and its broader therapeutic platform.
Building on Recent Momentum
The successful financing follows a period of sustained progress for N-Zyme Biomedical.
Recent milestones include the launch of the company’s Phase 2 clinical program for laryngopharyngeal reflux, continued expansion of its global intellectual property portfolio, and increasing interest from clinicians, investors, and strategic collaborators.
The company believes these achievements have helped establish a strong foundation for continued development while enhancing confidence in its long-term growth strategy.
As additional clinical data become available, N-Zyme expects to further evaluate the potential of its pepsin inhibitor platform across multiple reflux-related indications.
With its Series A financing successfully completed, N-Zyme Biomedical is entering its next stage of clinical and corporate development. The additional capital provides the company with the resources needed to accelerate Phase 2 studies, expand scientific research, strengthen regulatory and manufacturing capabilities, and pursue strategic partnerships that support future growth.
By focusing on pepsin inhibition rather than conventional acid suppression, N-Zyme is pursuing a differentiated therapeutic strategy that has the potential to address important gaps in the treatment of reflux disease. If ongoing clinical studies continue to demonstrate positive results, the company’s investigational therapy could offer a new option for patients living with laryngopharyngeal reflux, PPI-refractory GERD, and other reflux-related conditions that remain difficult to treat with current standard therapies.
As the clinical development program advances, N-Zyme aims to generate the evidence necessary to support future regulatory submissions while continuing its mission of improving outcomes for millions of patients affected by chronic reflux disease worldwide.
About N-Zyme Biomedical
N-Zyme Biomedical is a clinical-stage biotechnology company developing first-in-class therapies targeting pepsin, a key driver of tissue damage in reflux disease. The company’s lead program is currently being evaluated in Phase 2 clinical trials for laryngopharyngeal reflux (LPR), with additional development planned for patients with proton pump inhibitor (PPI)-refractory gastroesophageal reflux disease (GERD). Through its differentiated mechanism of action, N-Zyme aims to transform the treatment paradigm for reflux disease by addressing one of its underlying causes rather than simply reducing gastric acid.